Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H K van Halteren

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2016
Reply to 'Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents' by Saad and BuyseH K van Halteren
Anti-Cancer Drugs|February 6, 2003
Colorectal cancer in 2003: old principles, new strategiesH K van Halteren
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Large bowel mucosal metastases from breast cancerH K van Halteren, H Peters, P G Gerlag
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1997
5-Fluorouracil-based treatment of patients with advanced colorectal carcinoma outside clinical trials: importance of limited toxicityH K van Halteren, J J Keuning, G Vreugdenhil
Anticancer Research|February 26, 2004
Cancer cachexia: what is known about its etiology and what should be the current treatment approach?H K van Halteren, G P Bongaerts, D J Wagener
Nederlands Tijdschrift Voor Geneeskunde|July 20, 2007
[Myocardial ischaemia as a result of treatment with capecitabine]H K van Halteren, A H Liem, A S T Planting
Anticancer Research|July 1, 1997
Advanced colorectal cancer, refractory to infusional fluorouracil treatment: efficacy of second line fluorouracil in combination with a different biochemical modulationH K van Halteren, D J Wagener, G Vreugdenhil, et al.
Lancet (London, England)|September 8, 2004
Cancer and psychosocial distress: frequent companionsH K van Halteren, G P A Bongaerts, D J Th Wagener
International Journal of Cancer|May 1, 1994
Association of H-ras mutations with adenocarcinomas of the parotid glandH K van Halteren, B Top, W J Mooi, et al.
Journal of Hepatology|July 1, 1997
Spontaneous regression of hepatocellular carcinomaH K van Halteren, J M Salemans, H Peters, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2016
Reply to 'Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents' by Saad and BuyseH K van Halteren
Anti-Cancer Drugs|February 6, 2003
Colorectal cancer in 2003: old principles, new strategiesH K van Halteren
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Large bowel mucosal metastases from breast cancerH K van Halteren, H Peters, P G Gerlag
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1997
5-Fluorouracil-based treatment of patients with advanced colorectal carcinoma outside clinical trials: importance of limited toxicityH K van Halteren, J J Keuning, G Vreugdenhil
Anticancer Research|February 26, 2004
Cancer cachexia: what is known about its etiology and what should be the current treatment approach?H K van Halteren, G P Bongaerts, D J Wagener
Nederlands Tijdschrift Voor Geneeskunde|July 20, 2007
[Myocardial ischaemia as a result of treatment with capecitabine]H K van Halteren, A H Liem, A S T Planting
Anticancer Research|July 1, 1997
Advanced colorectal cancer, refractory to infusional fluorouracil treatment: efficacy of second line fluorouracil in combination with a different biochemical modulationH K van Halteren, D J Wagener, G Vreugdenhil, et al.
Lancet (London, England)|September 8, 2004
Cancer and psychosocial distress: frequent companionsH K van Halteren, G P A Bongaerts, D J Th Wagener
International Journal of Cancer|May 1, 1994
Association of H-ras mutations with adenocarcinomas of the parotid glandH K van Halteren, B Top, W J Mooi, et al.
Journal of Hepatology|July 1, 1997
Spontaneous regression of hepatocellular carcinomaH K van Halteren, J M Salemans, H Peters, et al.
Pageof 3